The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab
alone and in combination with chemotherapy. This will be a 3-arm, multi-center, open-label,
non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients
will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with
non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may
receive either cohorts 1 and 2.
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University Naiyer Rizvi
Collaborators:
Massachusetts General Hospital Merck Sharp & Dohme Corp. National Cancer Institute (NCI)